| Autor: |
A, Jouret-Mourin, A, Hoorens, G, De Hertogh, J, Vanderveken, P, Demetter, E, Van Cutsem |
| Rok vydání: |
2012 |
| Předmět: |
|
| Zdroj: |
Acta gastro-enterologica Belgica. 75(1) |
| ISSN: |
1784-3227 |
| Popis: |
The Human Epidermal growth factor Receptor 2 (HER2) has been established as a key player in the development of certain human tumors. ToGA trial has demonstrated that the addition of the monoclonal antibody blocking HER2 receptor, trastuzumab (Herceptin®), to chemotherapy significantly improves overall survival of patients with HER2-positive advanced or metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. Therefore, it is essential that pathologists guarantee an accurate testing of HER2 status in these tumours. Following the international recommendations and the Belgian criteria for reimbursement of trastuzumab, a consortium of expert pathologists (Belgian Working Group Molecular Pathology) proposes an adaptation of the international guidelines in order to develop strategies for optimal performance, interpretation and reporting assays. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
